Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Bryan Oronsky

Showing results (91-100 of 115) with videos related to

Pageof 12
Sort By:
Neoplasia (New York, N.Y.)|October 18, 2015
Confirmatory Trials in the Evaluation of Anticancer Medicinal Products in Man--PFS2: A Measure of Therapeutic Action-At-A-DistanceBryan Oronsky, Corey A Carter, Tony R Reid, et al.
Translational Lung Cancer Research|February 11, 2021
In small cell lung cancer patients treated with RRx-001, a downregulator of CD47, decreased expression of PD-L1 on circulating tumor cells significantly correlates with clinical benefitYusuke Tomita, Bryan Oronsky, Nacer Abrouk, et al.
Medical Oncology (Northwood, London, England)|July 6, 2016
Targeting tumor hypoxia with the epigenetic anticancer agent, RRx-001: a superagonist of nitric oxide generationMarcel H Fens, Pedro Cabrales, Jan Scicinski, et al.
Case Reports in Oncology|May 18, 2017
A Case of Paraneoplastic Cushing Syndrome Presenting as Hyperglycemic Hyperosmolar Nonketotic SyndromeChristina E Brzezniak, Nicole Vietor, Patricia E Hogan, et al.
Redox Biology|February 7, 2017
The Development Of RRx-001, A Novel Nitric-Oxide-Mediated Epigenetically Active Anticancer AgentJan Scicinski, George Fisher, Corey Carter, et al.
Journal of Medicinal Chemistry|May 27, 2021
Discovery of RRx-001, a Myc and CD47 Downregulating Small Molecule with Tumor Targeted Cytotoxicity and Healthy Tissue Cytoprotective Properties in Clinical DevelopmentBryan Oronsky, XiaoNing Guo, XiaoHui Wang, et al.
American Journal of Cancer Research|October 13, 2022
Subset analysis of safety and efficacy in asian patients treated with RRx-001 across three clinical trialsXiaoning Guo, Xiaohui Wang, Sui Shen, et al.
Biochimica Et Biophysica Acta. Reviews on Cancer|August 23, 2020
COVID-19 and cancer: A guide with suggested COVID-19 rule-out criteria to support clinical decision-makingChristopher Larson, Bryan Oronsky, Sharad Goyal, et al.
Case Reports in Oncology|April 12, 2016
Immune Reactivity and Pseudoprogression or Tumor Flare in a Serially Biopsied Neuroendocrine Patient Treated with the Epigenetic Agent RRx-001Corey A Carter, Bruno Schmitz, P Gabriel Peterson, et al.
Frontiers in Pharmacology|May 10, 2021
RRx-001 Radioprotection: Enhancement of Survival and Hematopoietic Recovery in Gamma-Irradiated MiceKimberly J Jurgensen, William K J Skinner, Bryan Oronsky, et al.
Pageof 12

Showing results (91-100 of 115) with videos related to

Sort By:
Pageof 12
Neoplasia (New York, N.Y.)|October 18, 2015
Confirmatory Trials in the Evaluation of Anticancer Medicinal Products in Man--PFS2: A Measure of Therapeutic Action-At-A-DistanceBryan Oronsky, Corey A Carter, Tony R Reid, et al.
Translational Lung Cancer Research|February 11, 2021
In small cell lung cancer patients treated with RRx-001, a downregulator of CD47, decreased expression of PD-L1 on circulating tumor cells significantly correlates with clinical benefitYusuke Tomita, Bryan Oronsky, Nacer Abrouk, et al.
Medical Oncology (Northwood, London, England)|July 6, 2016
Targeting tumor hypoxia with the epigenetic anticancer agent, RRx-001: a superagonist of nitric oxide generationMarcel H Fens, Pedro Cabrales, Jan Scicinski, et al.
Case Reports in Oncology|May 18, 2017
A Case of Paraneoplastic Cushing Syndrome Presenting as Hyperglycemic Hyperosmolar Nonketotic SyndromeChristina E Brzezniak, Nicole Vietor, Patricia E Hogan, et al.
Redox Biology|February 7, 2017
The Development Of RRx-001, A Novel Nitric-Oxide-Mediated Epigenetically Active Anticancer AgentJan Scicinski, George Fisher, Corey Carter, et al.
Journal of Medicinal Chemistry|May 27, 2021
Discovery of RRx-001, a Myc and CD47 Downregulating Small Molecule with Tumor Targeted Cytotoxicity and Healthy Tissue Cytoprotective Properties in Clinical DevelopmentBryan Oronsky, XiaoNing Guo, XiaoHui Wang, et al.
American Journal of Cancer Research|October 13, 2022
Subset analysis of safety and efficacy in asian patients treated with RRx-001 across three clinical trialsXiaoning Guo, Xiaohui Wang, Sui Shen, et al.
Biochimica Et Biophysica Acta. Reviews on Cancer|August 23, 2020
COVID-19 and cancer: A guide with suggested COVID-19 rule-out criteria to support clinical decision-makingChristopher Larson, Bryan Oronsky, Sharad Goyal, et al.
Case Reports in Oncology|April 12, 2016
Immune Reactivity and Pseudoprogression or Tumor Flare in a Serially Biopsied Neuroendocrine Patient Treated with the Epigenetic Agent RRx-001Corey A Carter, Bruno Schmitz, P Gabriel Peterson, et al.
Frontiers in Pharmacology|May 10, 2021
RRx-001 Radioprotection: Enhancement of Survival and Hematopoietic Recovery in Gamma-Irradiated MiceKimberly J Jurgensen, William K J Skinner, Bryan Oronsky, et al.
Pageof 12